Clinically validated digital therapeutics in oncology

In recent years, digital health technologies have been increasingly integrated into oncology, from patient-reported outcomes (PROs) to AI-driven decision support. One of the main challenges is ensuring that these solutions are supported by robust, long-term clinical evidence. Demonstrating not only usability but also measurable effects on survival and quality of life is essential before these tools can be considered part of standard cancer care.

Among the digital therapeutics evaluated to date, we can take the example of Moovcare®, which has accumulated more than a decade of clinical research across randomized trials and real-world studies in France, Spain, and the United States. Its approach is based on a simple principle: patients complete a weekly questionnaire, developed by physicians. Data are analyzed by an algorithm designed to detect early signs of relapses or complications. Notifications are then transmitted to a medical team, who reviews the information and, when necessary, contacts the patient. If a medical intervention is required, the oncologist is informed so that appropriate action can be taken before the patient’s condition deteriorates. It has already been used by thousands of patients. This approach complements conventional imaging and routine visits, supporting more timely clinical management.

Studies have shown an increase in overall survival of 7.6 months compared with standard follow-up, alongside improved quality of life, fewer hospitalizations, and adherence rates above 90%. Economic analyses also point to reductions of more than 10% in annual hospitalization costs. These results have been presented at international oncology congresses such as ASCO and published in leading peer-reviewed journals including JNCI, JTO, and JAMA.

In 2025, Moovcare® obtained CE Mark certification under the European Regulation (EU) 2017/745 for Moovcare® Toxicity, designed to monitor treatment-related toxicities across all cancer types. At the same time, Moovcare® Lung renewed its CE certification. This dual recognition reflects both regulatory compliance and the maturity of clinical validation achieved by the solutions.

Clinical practice feedback aligns with the trial results. Physicians report that this tool offers a structured approach to capturing patient-reported outcomes and supports earlier therapeutic decision-making. Patients describe the tool as easy to use and reassuring, with consistently high satisfaction across studies. Integration into clinical workflows has been feasible without compromising safety or oversight.

The broader lesson is clear: digital health in oncology can deliver real value. Long-term evaluation, regulatory approval, and integration into care pathways are critical for adoption at scale.

Moovcare® illustrates this pathway from concept to validated digital therapeutic. It is now entering a phase of international expansion. Its trajectory highlights how digital monitoring, grounded in robust evidence, can contribute to earlier relapse detection, better quality of life, and more efficient use of healthcare resources in cancer care.